Effectiveness of Buzzy on Pain and Anxiety in Children and Adolescents Undergoing Needle Procedures: A Meta-Analysis.

Holist Nurs PractJul 14, 2025 (epub)
Clinical ResearchPediatrics

Luigi Apuzzo, Francesco Burrai, Sonia Sellami et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed cold vibration delivered by the Buzzy device for pain and anxiety during venipuncture or injection in children and adolescents. It included 16 randomized controlled trials with 1486 patients, identified through searches of six databases in January 2025. Compared with control, Buzzy significantly reduced pain (SMD -1.06, 95% confidence interval [-1.39, -0.72], P < .00001) and anxiety (SMD -1.60, 95% confidence interval [-2.70, -0.51], P = .004). The recommendation direction favored Buzzy, but its strength was rated weak.

Key findings

  • Across 16 randomized controlled trials involving 1486 patients, Buzzy reduced pain versus control (SMD -1.06, 95% confidence interval [-1.39, -0.72], P < .00001).
  • Anxiety was lower with Buzzy than control (SMD -1.60, 95% confidence interval [-2.70, -0.51], P = .004).
  • The recommendation direction favored Buzzy, while the strength of recommendation was rated weak.

Why it matters

Needle procedures can involve pain and anxiety for pediatric patients. This synthesis indicates that cold vibration may help reduce both outcomes, offering evidence for a non-pharmacological approach during venipuncture or injection. The weak recommendation rating is important context: the pooled results are favorable, but the authors’ assessment does not support treating the intervention as a strongly established recommendation.

What to keep in mind

The recommendation was rated weak, indicating limited strength of the evidence-based recommendation.

Source

Published in Holist Nurs Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.